Claritev (NYSE:CTEV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Claritev (NYSE:CTEV) from a sell rating to a hold rating in a report released on Saturday.

Several other equities analysts also recently weighed in on the company. Zacks Research downgraded Claritev from a “hold” rating to a “strong sell” rating in a research report on Friday, July 17th. Barclays assumed coverage on shares of Claritev in a research note on Friday, April 24th. They set an “overweight” rating and a $28.00 price objective for the company. Piper Sandler set a $61.00 price objective on shares of Claritev in a research report on Wednesday, June 3rd. Canaccord Genuity Group increased their target price on shares of Claritev from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Finally, Citigroup restated a “buy” rating on shares of Claritev in a report on Wednesday, May 13th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Claritev presently has an average rating of “Hold” and a consensus price target of $39.50.

Claritev Price Performance

NYSE:CTEV opened at $33.54 on Friday. The firm has a market capitalization of $571.86 million, a price-to-earnings ratio of -1.97 and a beta of 0.74. Claritev has a 1 year low of $11.50 and a 1 year high of $74.07. The business has a 50 day simple moving average of $29.00 and a 200-day simple moving average of $23.78.

Institutional Investors Weigh In On Claritev

A number of institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. bought a new position in Claritev in the 3rd quarter valued at $1,245,000. Vanguard Group Inc. purchased a new stake in Claritev in the third quarter worth $27,483,000. Ameritas Investment Partners Inc. bought a new stake in shares of Claritev during the third quarter worth $42,000. Russell Investments Group Ltd. bought a new stake in shares of Claritev during the third quarter worth $369,000. Finally, Legal & General Group Plc purchased a new stake in shares of Claritev during the third quarter valued at $45,000. 87.15% of the stock is owned by institutional investors.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.